CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies ...
We transfer coverage of CSL, a global leader in plasma therapies, influenza vaccinations, and iron and kidney products. Shares have plummeted over 60% in the last two years on several earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results